Carol D Weiss

List of Publications by Year
in descending order

42 papers	2,022 citations	331670 21 h-index	254184 43 g-index
44 all docs	44 docs citations	44 times ranked	2021 citing authors

#	Article	IF	Citations
1	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. Journal of Virology, 2022, 96, JVI0111021.	3.4	29
2	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	27.8	117
3	SARS-CoV-2 BA.1 variant is neutralized by vaccine boosterâ€“elicited serum but evades most convalescent serum and therapeutic antibodies. Science Translational Medicine, 2022, 14, eabn8543.	12.4	75
4	Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018â€“2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin. Clinical Infectious Diseases, 2021, 73, e4312-e4320.	5.8	11
5	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS ONE, 2021, 16, e0248348.	2.5	102
6	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses, 2021, 13, 2485.	3.3	23
7	Neutralizing and Neuraminidase Antibodies Correlate With Protection Against Influenza During a Late Season A/H3N2 Outbreak Among Unvaccinated Military Recruits. Clinical Infectious Diseases, 2020, 71, 3096-3102.	5.8	22
8	Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin. Vaccines, 2020, 8, 382.	4.4	25
9	Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it. PLoS ONE, 2019, 14, e0222436.	2.5	11
10	Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses. Journal of Virology, 2019, 93, .	3.4	2
11	Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination. Clinical Infectious Diseases, 2019, 68, 2067-2078.	5.8	5
12	Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies. Journal of Virology, 2018, 92, .	3.4	10
13	HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120. Journal of Virology, 2018, 92, .	3.4	18
14	Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic. Open Forum Infectious Diseases, 2017, 4, ofx023.	0.9	6
15	Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies. PLoS ONE, 2017, 12, e0175733.	2.5	15
16	Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies. PLoS ONE, 2016, 11, e0149149.	2.5	14
17	Serum Samples From Middle-aged Adults Vaccinated Annually with Seasonal Influenza Vaccines Cross-neutralize Some Potential Pandemic Influenza Viruses. Journal of Infectious Diseases, 2016, 213, 403-406.	4.0	6
18	Antibodies to Antigenic Site A of Influenza H7 Hemagglutinin Provide Protection against H7N9 Challenge. PLoS ONE, 2015, 10, e0117108.	2.5	32

#	Article	IF	Citations
19	Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein. PLoS ONE, 2015, 10, e0128562.	2.5	9
20	Influenza Virus M2 Protein Ion Channel Activity Helps To Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence during Transport to the Cell Surface. Journal of Virology, 2015, 89, 1975-1985.	3.4	42
21	Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity. Journal of Virology, 2015, 89, 10602-10611.	3.4	23
22	Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics. Retrovirology, 2014, 11, 86.	2.0	13
23	Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin. Influenza and Other Respiratory Viruses, 2013, 7, 480-490.	3.4	16
24	Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors. Viruses, 2012, 4, 3859-3911.	3.3	31
25	Trimeric, Coiled-coil Extension on Peptide Fusion Inhibitor of HIV-1 Influences Selection of Resistance Pathways. Journal of Biological Chemistry, 2012, 287, 8297-8309.	3.4	21
26	Selection with a Peptide Fusion Inhibitor Corresponding to the First Heptad Repeat of HIV-1 gp41 Identifies Two Genetic Pathways Conferring Cross-Resistance to Peptide Fusion Inhibitors Corresponding to the First and Second Heptad Repeats (HR1 and HR2) of gp41. Journal of Virology, 2011, 85, 12929-12938.	3.4	21
27	Cross-Neutralizing Antibodies to Pandemic 2009 H1N1 and Recent Seasonal H1N1 Influenza A Strains Influenced by a Mutation in Hemagglutinin Subunit 2. PLoS Pathogens, 2011, 7, e1002081.	4.7	37
28	Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. Journal of Virological Methods, 2010, 165, 305-310.	2.1	38
29	A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Virology, 2010, 407, 374-380.	2.4	20
30	Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge. Vaccine, 2010, 28, 699-706.	3.8	1
31	Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. Journal of Virological Methods, 2008, 153, 111-119.	2.1	94
32	Antibodies to the A27 Protein of Vaccinia Virus Neutralize and Protect against Infection but Represent a Minor Component of Dryvax Vaccineâ€“Induced Immunity. Journal of Infectious Diseases, 2007, 196, 1026-1032.	4.0	26
33	Human Immunodeficiency Virus (HIV) gp41 Escape Mutants: Cross-Resistance to Peptide Inhibitors of HIV Fusion and Altered Receptor Activation of gp120. Journal of Virology, 2005, 79, 4774-4781.	3.4	26
34	Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes. Journal of Virology, 2004, 78, 2627-2631.	3.4	87
35	Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood, 2004, 103, 1586-1594.	1.4	129
36	Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites. Journal of Virology, 2003, 77, 1666-1671.	3.4	134

#	Article	IF	Citations
37	Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates. Journal of Virology, 2002, 76, 6780-6790.	3.4	115
38	Peptides Corresponding to the Heptad Repeat Motifs in the Transmembrane Protein (gp41) of Human Immunodeficiency Virus Type 1 Elicit Antibodies to Receptor-Activated Conformations of the Envelope Glycoprotein. Journal of Virology, 2001, 75, 8859-8863.	3.4	56
39	Structure-Function Studies of the Self-Assembly Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41. Journal of Virology, 2000, 74, 5368-5372.	3.4	39
40	Capture of an early fusion-active conformation of HIV-1 gp41. Nature Structural Biology, 1998, 5, 276-279.	9.7	482
41	Studies of HIV-1 envelope glycoprotein-mediated fusion using a simple fluorescence assay. Aids, 1996, 10, 241-246.	2.2	33
42	NIAID recommendations for treating HIV infection. JAMA - Journal of the American Medical Association, 1994, 271, 1830-1830.	7.4	0